- Home
- CMPS vs IMTX Comparison
CMPS vs IMTX Comparison
Compare CMPS & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMPS | IMTX |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United Kingdom | Germany |
| Employees | N/A | 407 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | CMPS | IMTX |
|---|---|---|
| Price | $12.11 | $9.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $25.38 | $19.00 |
| AVG Volume (30 Days) | ★ 4.0M | 543.5K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.25 | $5.05 |
| 52 Week High | $14.76 | $12.41 |
Technical Indicators
Market Signals| Indicator | CMPS | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.69 | 37.00 |
| Support Level | $5.48 | $9.05 |
| Resistance Level | $14.76 | $10.64 |
| Average True Range (ATR) | 0.99 | 0.59 |
| MACD | -0.25 | -0.20 |
| Stochastic Oscillator | 35.33 | 19.11 |
Price Performance
Historical ComparisonAbout CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.